Wang Linglai Of Jinyu Medicine: The Core Advantage Of The Third-Party Medical Examination Is Specialization And Scale

"The advantages of the third-party medical examination lie in its specialization and scale. Jinyu is a company that can provide full life cycle testing items. At present, it can achieve 2700 tests, while the general tertiary hospitals do 800 to 1000 tests. In addition, it is large-scale, using the mode of industrialization to improve operational efficiency and reduce costs. " On September 26, Wang linglai, senior vice president of shangjinyu medical group, said in the "2020 China's big health industry summit" sponsored by the 21st century economic report.

Wang linglai mentioned that in the case of the new coronal pneumonia epidemic, in the early days, the nucleic acid detection in general tertiary hospitals could only do 100-200 cases a day, and the detection ability of some prefecture level cities was even weaker. At this time, the third-party medical examination played a complementary role and rapidly promoted the local daily detection capacity. The outbreak of new pneumonia is not only a test of our technology, but also a test of our logistics capabilities that are easily overlooked. In the early stage of the epidemic, many people were in the areas below the county level, and the local medical institutions and centers for Disease Control and prevention did not have the ability to detect nucleic acids, which put the cold chain logistics in a more challenging situation.

Wang linglai. Information map

According to the 2019 China Health and health statistical yearbook, the total income of the hospital in 2018 exceeded 300 billion yuan. According to the calculation that the inspection cost accounts for about 10% of the hospital's income and the proportion of inspection delivery accounts for 5%, the market share of the third-party medical examination is about 15 billion yuan.

In this regard, Wang linglai said: "the core value model of third-party medical examination is specialization and scale, that is, strengthening quality, focusing on technology, and large-scale testing. Through quality improvement, we have gained the recognition of hospitals and doctors. Through technological innovation, the number of testing items can reach 2700, while the general tertiary hospitals can only do 800 to 1000 tests. The detection items are complete, which can effectively reduce the possibility of missed diagnosis and misdiagnosis. Through the large-scale operation, we can reduce the cost of testing and save medical expenses

Since the outbreak of new crown pneumonia, Jinyu medical has carried out nucleic acid detection in 30 provinces, municipalities and Hong Kong, with a total of more than 21 million copies, accounting for nearly 1 / 10 of the country. The whole third-party medical examination industry accounts for 40% of the total nucleic acid detection in China. In Guangdong Province, it actively undertakes the screening of fever clinics, close contact groups and inpatients, nucleic acid detection of relevant departments and key enterprises, as well as the re enrollment and entry examination; in Hubei Province, it undertakes the preliminary screening tasks in Jingmen, Xianning, Tianmen and Xiaogan of Hubei Province; provides counterpart support to Jingzhou with the first batch of Guangdong medical teams; carries out nucleic acid testing under the entrustment of leishenshan hospital, Ten technical backbones were also sent to support the work of the laboratory.

Wang linglai pointed out that in the "post epidemic" period, the detection market will further increase. First of all, in the near future, will nucleic acid testing be reduced once the vaccine is available, which will lead to a decrease in the revenue of the third-party medical examination?

In this regard, Wang linglai said that it should not have a great impact. According to the current research, there are antibodies against new coronavirus in human body, and some cases have shown that there will be a certain attenuation. At the same time, the virus itself is mutating. Therefore, after vaccination, whether there is effective antibody, including whether there is attenuation and whether it can be sustained, will be the focus of future detection. In the future, it may not be the question "have you got any nucleic acid" after meeting each other, but "have you tested the antibody?" This huge amount of detection also requires the participation of the third-party testing institutions.

In addition, with the anti epidemic, the third-party medical examination has entered the vision of the government, especially public health procurement. In the future, more government procurement, even the medical service market, will further open the door to the third-party medical examination, thus increasing the market share of outsourcing.

Wang linglai analyzed that after the anti epidemic, the medical investment market will continue to warm up, investment and scientific and technological research and development will further heat up, and the third-party medical examination market will continue to be optimistic. It is widely predicted that after the mobile Internet, biotechnology innovation will be a new round of investment boom, especially after the medical examination is embedded in the closed loop of the medical Internet industry, the development momentum will be even stronger.